Effects of Intravitreal Injection of Ranibizumab or Conbercept Combined with AGV on Neovascular Glaucoma and Their Influence on VEGF and IL-6 Levels in Aqueous Humor
WANG Qian, ZHAO Xiaoxia, WU Juan, et al
Xining First People's Hospital, Qinghai Xining 810000, China
Abstract：Objective: To explore the effects of intravitreal injection of ranibizumab or conbercept combined with ahemd glaucoma valve (AGV) in the treatment of neovascular glaucoma (NVG) and their influence on vascular endothelial growth factor (VEGF) and interleukin- 6 (IL-6) levels in aqueous humor. Methods: A total of 96 patients (96 eyes) with NVG admitted to our hospital from January 2016 to May 2018 were selected, and the clinical data of all patients were retrospectively analyzed. Patients were divided into ranibizumab group (group A, 34 cases, 34 eyes), conbercept group (group B, 33 cases, 33 eyes) and control group (group C, 29 cases, 29 eyes) according to different treatment regimens. The neovascularization regression of iris and chamber angle surface was observed among patients. The intraocular pressure, visual acuity and aqueous humor VEGF and IL-6 levels in the three groups were compared before and after surgery. The incidence rate of postoperative complications was recorded. Results: The neovascularization regression of iris and chamber angle surface was good in groups A and B, and there were still new blood vessels in group C, and the difference among the three groups was significant (P<0.05), and there was no statistical difference between group A and group B (P>0.05). There were statistical significance in the between-group effect, time-point effect and interaction of time-point and between-group of intraocular pressure among the three groups before surgery and at 2 w, 1 month, 3 months and 6 months after surgery (P<0.05). The intraocular pressure in the three groups at 2 w, 1 month, 3 months and 6 months after surgery was significantly decreased compared with that before surgery, and the improvement of visual acuity in group A and group B was better than that in group C at 6 months after surgery (P<0.05), but there were no significant differences in the above indexes between group A and group B (P>0.05). There was no significant difference in visual acuity among the three groups at 6 months after surgery (P<0.05). After treatment, the levels of VEGF and IL-6 in aqueous humor were decreased significantly in the three groups compared with those before treatment (P<0.05), and the comparisons of differences of the above indexes in the three groups before and after treatment were statistically significant (P<0.05). There was no statistically significant difference in the incidence rate of complications among the three groups (P>0.05). Conclusion: Intravitreal injection of ranibizumab or conbercept combined with AGV both have reliable efficacy and safety in the treatment of NVG, and they can effectively reduce intraocular pressure, improve visual acuity, promote neovascularization regression, and inhibit the expression of vasoactive substances and inflammatory factors in aqueous humor. The two drugs have comparable treatment effects.
王茜, 赵晓霞, 吴娟, 李海青, 秦小萍. 雷珠单抗康柏西普玻璃体注射联合AGV治疗新生血管性青光眼的效果及对房水VEGF IL-6水平的影响[J]. 河北医学, 2021, 27(5): 789-794.
WANG Qian, ZHAO Xiaoxia, WU Juan, et al. Effects of Intravitreal Injection of Ranibizumab or Conbercept Combined with AGV on Neovascular Glaucoma and Their Influence on VEGF and IL-6 Levels in Aqueous Humor. HeBei Med, 2021, 27(5): 789-794.
2021, Vol. 27 
冀公网安备13080202000677号